Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
User feedback can provide valuable insights into no fee travel points cards. Discover what real users are saying to make an informed choice.
16,799 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Scotiabank boosted Cameco's price target to $175 as a global push for nuclear power gains traction and a new supply d...
The idea of lifelong renters isn’t just a buzzword—it's reshaping how landlords approach financing, property manageme...
Micron Technology rides a surge in AI memory demand, delivering stronger margins and robust cash flow. As the company...
Cognex is navigating a world of AI-powered machine vision in manufacturing. This article breaks down the Q1 2026 resu...
The AI boom is reshaping the chip landscape. This guide identifies the best chips stocks right now and shows investor...
Micron stock surged 700% over the past year, driven by AI memory demand. This guide breaks down what powered the rall...
When the market rallies but your upside seems limited, it helps to look for growth stocks down right now. This articl...
Legislation momentum revives the XRP ETF narrative as institutions eye regulated XRP exposure via XRPFi on Flare, wit...
DRAM prices in Korea jumped nearly 500% year over year as Micron, Samsung, and SK Hynix tighten control, turning memo...
A high-profile Nvidia deal has propelled a semiconductor stock into the spotlight. This article breaks down whether t...
When a global intelligence stock sinking trend hits the market, it signals shifts in growth expectations and margins....